ARGX-109
ARGX-109
ARGX-109 is a monoclonal antibody developed by the biotechnology company Argenx. It is part of a class of therapeutic agents designed to modulate the immune system, specifically targeting pathways involved in autoimmune diseases. ARGX-109 is currently under investigation for its potential to treat various autoimmune conditions by modulating the activity of specific immune cells.
Mechanism of Action[edit | edit source]
ARGX-109 functions by targeting a specific protein involved in the immune response. This protein, often overactive in autoimmune diseases, plays a crucial role in the activation and proliferation of immune cells that mistakenly attack the body's own tissues. By binding to this protein, ARGX-109 can inhibit its activity, thereby reducing the inappropriate immune response and alleviating symptoms of autoimmune diseases.
Clinical Development[edit | edit source]
ARGX-109 is in the early stages of clinical development. Preclinical studies have shown promising results in animal models, demonstrating the antibody's ability to modulate immune responses effectively. The drug is currently undergoing Phase I clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers.
Phase I Trials[edit | edit source]
The Phase I trials of ARGX-109 are designed to evaluate the safety profile of the drug. These trials involve a small number of healthy participants who receive varying doses of ARGX-109. Researchers monitor these participants for any adverse effects and collect data on how the drug is metabolized and excreted by the body.
Future Directions[edit | edit source]
Following successful Phase I trials, ARGX-109 will progress to Phase II trials, where its efficacy in patients with specific autoimmune diseases will be tested. These trials will help determine the optimal dosing regimen and further assess the drug's safety and effectiveness.
Potential Indications[edit | edit source]
ARGX-109 is being explored for use in several autoimmune diseases, including:
Each of these conditions involves an overactive immune response, making them potential targets for ARGX-109 therapy.
Also see[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
- [Argenx Official Website](https://www.argenx.com)
- [ClinicalTrials.gov](https://www.clinicaltrials.gov)
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
